Alcoholic Hepatitis Treatment Global Market Report 2024

The alcoholic hepatitis treatment market size has grown strongly in recent years. It will grow from $2.95 billion in 2023 to $3.18 billion in 2024 at a compound annual growth rate (CAGR) of 7.9%. The growth observed in the historic period for alcoholic hepatitis treatment can be attributed to factors such as a high prevalence of alcohol abuse, increased awareness and diagnostics, government initiatives addressing alcoholism, a rise in healthcare expenditure, and the impact of public health campaigns.

The alcoholic hepatitis treatment market size is expected to see strong growth in the next few years. It will grow to $4.32 billion in 2028 at a compound annual growth rate (CAGR) of 7.9%. The anticipated growth in the forecast period for alcoholic hepatitis treatment is expected to be driven by factors such as the emergence of novel therapies and a promising drug pipeline, the adoption of precision medicine approaches, an enhanced understanding of disease pathogenesis, a rising focus on liver health, and the implementation of public health policies addressing alcohol abuse. Major trends in the forecast period include the adoption of personalized medicine approaches, trends in liver transplantation, the integration of telemedicine and remote monitoring, collaborative research initiatives, and the development of innovative drug solutions.

The escalating prevalence of liver diseases stemming from alcohol consumption is poised to be a significant driver fueling the expansion of the market for alcoholic hepatitis treatment. Alcoholic liver disease manifests as a result of impaired liver function. The liver, responsible for numerous physiological functions such as blood detoxification and bile production aiding digestion, experiences damage due to alcohol consumption. Treatment for alcoholic hepatitis targets liver inflammation in affected patients, often necessitating therapy in a hospital setting for those with severe manifestations of the condition. For instance, data from the National Library of Medicine in December 2021 predicted that an increase in alcohol use of one year during the COVID-19 pandemic could lead to 8,000 additional alcohol-related liver disease-related deaths, 18,700 cases of liver failure, and 1,000 instances of liver cancer by 2040. Hence, the heightened prevalence of alcohol-induced liver diseases acts as a significant impetus propelling the alcoholic hepatitis treatment market's growth.

The burgeoning emphasis on personalized medicine is anticipated to drive the expansion of the alcoholic hepatitis treatment market in the foreseeable future. Personalized medicine denotes an innovative medical approach that considers individual variations in patients' genetic makeup, environments, and lifestyles. This approach enables tailored treatment strategies, encompassing the customization of therapies, identification of susceptibility factors, optimized medication selection, individualized risk evaluation, and mitigation of adverse effects. It fosters patient engagement and compliance by aligning treatment plans with individual needs. For example, reports published by STAT in October 2022 indicated the availability of over 75,000 genetic testing products and 300 personalized medicines. This surging focus on personalized medicine stands as a significant catalyst propelling the growth of the alcoholic hepatitis treatment market.

Product innovation stands as a prominent and increasingly adopted trend within the alcoholic hepatitis treatment market. Companies engaged in this sector are placing significant emphasis on pioneering new products to maintain their competitive edge. An illustrative example is the July 2022 release by Roche Holding AG of the Elecsys HCV Duo, a groundbreaking dual antibody and antigen diagnostic test for hepatitis C virus (HCV). This innovative test enables independent and simultaneous detection of HCV antigen and antibody status using a single human plasma or serum sample. It aids in identifying patients in recovery or exhibiting chronic infection symptoms that might lead to conditions such as liver cancer or early-stage infections. The early manifestation of HCV's core antigen during infection, utilized as an indicator of ongoing viral replication, enables physicians to diagnose active HCV at an earlier stage compared to using solely antibody assays, enhancing diagnostic capabilities.

Prominent entities in the alcoholic hepatitis treatment market are channeling their efforts towards product development, specifically focusing on immunoassays, as a strategic driver for revenue generation. Immunoassays represent a type of biochemical testing method leveraging antibodies' specific binding to antigens to detect and quantify the presence or concentration of a target molecule (analyte) in a sample. For instance, in November 2023, F. Hoffmann-La Roche Ltd. unveiled Elecsys HBeAg quant, an immunoassay designed to measure hepatitis B e antigen (HBeAg) levels in human serum and plasma in both qualitative and quantitative formats. It serves as a predictive tool for chronic active hepatitis and an early indicator of acute hepatitis B infection. This test aids in diagnosing and monitoring individuals with hepatitis B virus infection when complemented with supplementary laboratory findings and clinical data. The Elecsys HBeAg quant, compatible with Roche's Cobas e analyzers, is intended for use with samples from patients with known positive results as well as those with an undetermined HBeAg status.

In October 2022, the France-based biotechnology company Genfit completed the acquisition of Versantis AG for an undisclosed amount. This strategic move enhances GENFIT's leadership position in acute-on-chronic liver failure (ACLF) and significantly broadens its pipeline. The acquisition brings valuable assets to GENFIT's portfolio, including VS-01-ACLF, a Phase 2-ready program based on first-in-class scavenging liposomes technology, VS-01-UCD, a pediatric program targeting urea cycle disorder (UCD), and VS-02-HE, an early-stage program focusing on hepatic encephalopathy (HE). Versantis AG, based in Switzerland, is a biotech company specializing in the development of therapeutics for hepatitis and alcohol-related liver diseases.

Major companies operating in the alcoholic hepatitis treatment market report are Pfizer Inc., Johnson & Johnson Services Inc., F. Hoffmann-La Roche Ltd., AbbVie Inc., Novartis AG, Sanofi PLC, Bristol-Myers Squibb Company, GlaxoSmithKline PLC, Torrent Pharmaceuticals Ltd., Takeda Pharmaceutical Company Limited, Gilead Sciences Inc., Merck KGaA, Viatris Inc., Teva Pharmaceutical Industries Ltd., AstraZeneca PLC, Cadila Pharmaceuticals, Sun Pharmaceutical Industries Ltd., Mylan Inc., Dr. Reddy’s Laboratories Ltd., Cipla Ltd., Hikma Pharmaceuticals PLC, Mallinckrodt Pharmaceuticals, Alkermes PLC, Intercept Pharmaceuticals Inc., Apotex Inc., Durect Corp.

North America was the largest region in the alcoholic hepatitis treatment market in 2023. It is expected to be the fastest-growing region in the forecast period. The regions covered in the alcoholic hepatitis treatment market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the alcoholic hepatitis treatment market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The primary modalities of treatment for alcoholic hepatitis include pharmaceutical interventions and stem cell therapy. Pharmaceutical treatment entails the use of medications, excluding food, to prevent, detect, treat, or alleviate the symptoms of diseases or abnormal conditions. Drug classes such as corticosteroids, hemorheologic agents, monoclonal antibodies, anabolic steroids, and others are administered through oral and injectable routes. These treatments are typically provided by healthcare facilities, clinics, and private treatment centers.

The alcoholic hepatitis treatment market research report is one of a series of new reports that provides alcoholic hepatitis treatment market statistics, including alcoholic hepatitis treatment industry global market size, regional shares, competitors with an alcoholic hepatitis treatment market share, detailed alcoholic hepatitis treatment market segments, market trends and opportunities, and any further data you may need to thrive in the alcoholic hepatitis treatment industry. This alcoholic hepatitis treatment market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The alcoholic hepatitis treatment market consists of revenues earned by entities by providing infection surveillance, ulcer prophylaxis, and liver transplantation. The market value includes the value of related goods sold by the service provider or included within the service offering. The alcoholic hepatitis treatment market also includes sales of anti-inflammatory medication such as steroids, pentoxifylline, and glucocorticoids. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.